

## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

# **Single Technology Appraisal**


# Filgotinib for treating active axial spondyloarthritis ID6594

## **Provisional Stakeholder List**

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
Company	General
Alfasigma UK Ltd (filgotinib)	All Wales Therapeutics and Toxicology
	Centre
Patient/carer groups	Allied Health Professionals Federation
Action on Pain	Board of Community Health Councils in
Arthritis Action	Wales
Arthritis and Musculoskeletal Alliance	British National Formulary
Brain and Spine Foundation	Care Quality Commission
National Axial Spondyloarthritis Society	Department of Health - Northern Ireland
Pain Concern	Healthcare Improvement Scotland
Pain UK	Medicines and Healthcare products
South Asian Health Foundation	Regulatory Agency
Specialised Healthcare Alliance	<ul> <li>National Association of Primary Care</li> </ul>
• STEPS	<ul> <li>National Pharmacy Association</li> </ul>
Versus Arthritis	NHS Confederation
	NHS Wales Joint Commissioning
Healthcare professional groups	Committee
British Geriatrics Society	Scottish Medicines Consortium
British Myology Society	Welsh Government
British Orthopaedic Association	
British Pain Society	Possible comparator companies
British Society for Paediatric and	ADVANZ Pharma (golimumab)
Adolescent Rheumatology	AbbVie (adalimumab, upadacitinib)
British Society for Rheumatology	Amgen (adalimumab)
<ul> <li>Chartered Society of Physiotherapy</li> </ul>	Biogen Biosimilars (adalimumab,
<ul> <li>Physiotherapy Pain Association</li> </ul>	etanercept, infliximab)
<ul> <li>Primary Care Rheumatology &amp;</li> </ul>	Celltrion Healthcare (adalimumab,
Musculoskeletal Medicine Society	infliximab)
Royal College of General Practitioners	Eli Lilly (ixekizumab)
Royal College of Nursing	Fresenius Kabi (adalimumab)
Royal College of Occupational	Janssen-Cilag (infliximab, golimumab)
Therapists	Novartis (secukinumab)
Royal College of Pathologists	Pfizer (etanercept, infliximab, tofacitinib)
Royal College of Physicians	Sandoz (adalimumab, etanercept,
Royal Pharmaceutical Society	infliximab)
Royal Society of Medicine	UCB Pharma (bimekizumab,
	certolizumab pegol)

Provisional stakeholder list for the evaluation of filgotinib for treating active axial spondyloarthritis ID6594

Issue date: December 2025



Provisional Consultees	Provisional Commentators (no right to submit or appeal)
Society for Endocrinology	Relevant research groups
UK Clinical Pharmacy Association	Bone Research Society
	Chronic Pain Policy Coalition
<u>Others</u>	Cochrane Musculoskeletal Group
<ul> <li>Department of Health and Social Care</li> </ul>	Genomics England
NHS England	MRC Clinical Trials Unit
	National Institute for Health Research
	Orthopaedic Research UK
	Pain Relief Foundation
	Society for Back Pain Research
	Associated Public Health groups
	Public Health Wales
	UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

#### Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

#### Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.


The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Provisional stakeholder list for the evaluation of filgotinib for treating active axial spondyloarthritis

Issue date: December 2025

© National Institute for Health and Care Excellence 2026. All rights reserved.



### Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.